Frontotemporal dementia affects people at a younger age than most other forms of dementia, often striking between 45 and 65 years old. While there is currently no cure or way to slow the disease, medical professionals can help manage symptoms and improve quality of life through a combination of medications, therapies, and supportive care strategies.

Understanding Treatment Goals for Frontotemporal Dementia

When someone receives a diagnosis of frontotemporal dementia, the focus of treatment shifts to managing symptoms and maintaining quality of life for as long as possible. Unlike some other medical conditions where therapy aims to reverse or cure the disease, treatment for frontotemporal dementia centers on controlling behavioral changes, preserving communication abilities, and supporting movement difficulties that develop over time.^[1][2]

The approach to treatment depends heavily on which type of frontotemporal dementia a person has and which symptoms are most prominent. Someone with behavioral variant frontotemporal dementia may need different interventions than someone with primary progressive aphasia, where language difficulties are the main concern. Similarly, the stage of the disease influences treatment decisions, as early symptoms may respond to different strategies than those that appear later.^[3]

Medical societies and healthcare organizations have established standard treatments that doctors can offer today, even though these do not stop the disease from progressing. At the same time, researchers around the world are actively testing new therapies in clinical trials, searching for treatments that might one day slow or halt the underlying disease process. This ongoing research represents hope for future generations, even as current patients benefit from symptomatic care.^[4]

Standard Treatment Approaches

The cornerstone of standard treatment for frontotemporal dementia involves addressing the behavioral and psychiatric symptoms that can be most distressing for both patients and their families. Doctors often turn to a class of medications called selective serotonin reuptake inhibitors, or SSRIs, which were originally developed to treat depression but have shown benefits in managing several frontotemporal dementia symptoms.^[11][12]

SSRIs work by increasing the level of serotonin, a chemical messenger in the brain that influences mood and behavior. In people with frontotemporal dementia, these medications may help control a range of difficult symptoms including apathy, depression, anxiety, agitation, and compulsive behaviors. They are considered relatively safe in the dementia population compared to other psychiatric medications. Common examples include medications that healthcare providers can prescribe after careful evaluation of the individual’s specific symptoms.^[12]

When SSRIs alone do not adequately control severe behavioral problems, doctors may sometimes consider antipsychotic medications. However, these are used rarely and with great caution because they carry significant risks in people with dementia, including increased chances of stroke and death. They might only be considered when aggressive behavior poses a serious risk to the person with dementia or to others around them, and only after other approaches have failed.^[12]

For movement problems that occur in some types of frontotemporal dementia, particularly those that overlap with Parkinson’s disease symptoms, treatment becomes more challenging. Medications containing carbidopa-levodopa, which work well for idiopathic Parkinson’s disease, generally do not help much with the movement difficulties seen in frontotemporal dementia. Still, some doctors may suggest a trial of these medications since a small percentage of patients might experience some improvement.^[11]

When frontotemporal dementia overlaps with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease, there is one medication called riluzole that has been approved for ALS treatment. This drug may modestly slow the progression of motor neuron disease and is sometimes used when FTD and ALS symptoms occur together.^[2][11]

Non-Medication Therapies

Beyond pharmaceuticals, a comprehensive treatment plan for frontotemporal dementia includes several types of professional therapy. Speech and language therapy plays a vital role for people experiencing communication difficulties, whether they struggle to find words, understand language, or physically form speech sounds. Speech therapists can teach strategies for compensating for language loss and help families develop better ways to communicate with their loved one. For those with swallowing difficulties, speech therapists also provide crucial evaluation and training to reduce the risk of choking or aspiration pneumonia.^[10][13]

Occupational therapy helps people maintain independence in daily activities for as long as possible. An occupational therapist assesses problem areas in everyday life, such as getting dressed, preparing meals, or managing personal hygiene, and works out practical solutions. This might involve teaching new techniques, suggesting adaptive equipment, or recommending modifications to the home environment that make tasks easier and safer.^[10]

Physical therapy addresses movement difficulties, helping people maintain mobility, balance, and strength. For those with stiffness, weakness, or coordination problems, a physical therapist designs exercises and strategies to preserve physical function and prevent falls. Regular physical activity, adapted to the person’s abilities, can also contribute to overall wellbeing and potentially slow physical decline.^[10]

Mental stimulation and social engagement remain important throughout the disease course. Memory cafes, which are drop-in sessions for people with memory problems and their caregivers, provide opportunities for social interaction, support, and advice in a welcoming environment. Maintaining meaningful activities, even as they need to be adapted to changing abilities, helps preserve quality of life and connection with others.^[10][16]

Managing Specific Behavioral Challenges

Behavioral changes in frontotemporal dementia can be among the most challenging aspects of the disease for families. When someone loses their ability to understand social norms, acts impulsively, or shows inappropriate behavior, it helps to remember that this is the disease affecting the brain, not a personal choice. Arguing or trying to reason with the person usually does not work because they cannot control these behaviors or even recognize that their behavior is unusual.^[15]

Non-pharmacological approaches should always be tried first before considering medication. These include establishing structured daily routines, using distraction techniques when problematic behaviors emerge, ensuring adequate physical activity and mental stimulation, and creating a calm, predictable environment. Caregivers learn to pick their battles, accepting behaviors that are not dangerous while setting boundaries around those that pose risks.^[16]

The duration of treatment in frontotemporal dementia extends throughout the disease course, which typically ranges from two to over twenty years, though the average is seven to thirteen years from symptom onset. Treatment plans need regular review and adjustment as symptoms evolve and new challenges emerge. What works at one stage may become less effective or unnecessary as the disease progresses.^[3]

Treatment in Clinical Trials

While standard treatments focus on managing symptoms, clinical trials are exploring whether it might be possible to actually slow or stop the disease process itself. Recent advances in understanding the molecular changes that cause frontotemporal dementia have opened new avenues for drug development, bringing cautious optimism to patients and families who hope for better treatment options in the future.^[11]

Understanding the Disease Targets

Scientists have discovered that frontotemporal dementia occurs when abnormal proteins accumulate inside brain cells and damage them. The two main culprits are proteins called tau and TDP-43. In a healthy brain, these proteins perform normal functions, but in frontotemporal dementia they become abnormal and group together, eventually killing the nerve cells. This understanding has given researchers specific molecular targets to aim therapies at.^[6]

Approximately 10 to 30 percent of people with behavioral variant frontotemporal dementia have a genetic cause for their disease, meaning they inherited a change in their DNA that makes the disease virtually inevitable. Having identified several genes responsible for familial frontotemporal dementia has been especially important for drug development because when researchers understand exactly what causes the disease in these cases, they have a clear target for treatment.^[6]

Phases of Clinical Trials

New treatments move through a series of testing phases before they can be approved for general use. Phase I trials focus primarily on safety, testing a new drug or therapy in a small number of people to determine what doses can be given safely and what side effects might occur. These early studies help researchers understand how the human body processes the experimental treatment.^[11]

Phase II trials expand to include more participants and begin to evaluate whether the treatment actually works. Researchers look for evidence that the experimental therapy affects the disease process or improves symptoms. They continue to monitor safety while gathering preliminary data on efficacy. Phase II studies in frontotemporal dementia might measure changes in behavior, language abilities, or brain imaging findings.^[11]

Phase III trials are large studies that compare the new treatment directly against either a placebo or the current standard treatment. These trials provide the definitive evidence needed for regulatory approval. They involve hundreds or even thousands of participants and track outcomes over extended periods. Only treatments that prove both safe and effective in phase III trials can be considered for approval by regulatory agencies like the U.S. Food and Drug Administration.^[11]

Phase IV trials occur after a treatment has been approved and is available for patients. These studies continue to monitor long-term effectiveness and safety in real-world settings, often involving even larger numbers of people than phase III trials.^[11]

Innovative Approaches Being Tested

Research into frontotemporal dementia treatments encompasses several promising strategies. Some studies focus on preventing the abnormal tau protein from accumulating or spreading through the brain. Others aim at the TDP-43 protein that causes a different type of frontotemporal dementia. These approaches represent potential disease-modifying therapies that could slow or stop progression rather than just masking symptoms.

Other clinical trials are testing whether existing drugs developed for different conditions might help with frontotemporal dementia symptoms. For example, researchers have explored whether medications that affect brain chemistry in specific ways might improve behavioral symptoms or cognitive function. While early results have been mixed, each study contributes valuable information about what works and what does not.

Genetic therapies represent another frontier in frontotemporal dementia research. For people with known genetic mutations that cause the disease, scientists are developing treatments that could potentially correct or compensate for the genetic defect. These highly targeted approaches are still in early stages but hold particular promise for familial forms of the disease.

Supporting Research Through Participation

One important way people with frontotemporal dementia and their families can contribute to progress is by participating in research studies and registries. The ALLFTD (ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration) Research Consortium, for example, tracks disease progression in people with frontotemporal dementia to help researchers better understand how the disease develops and changes over time. This information is crucial for designing better clinical trials and eventually finding effective treatments.^[6]

Genetic counseling and testing have become increasingly important for people with frontotemporal dementia. Understanding whether someone has a genetic form of the disease not only provides information for family members but also determines eligibility for certain clinical trials. As treatments targeting specific genetic mutations are developed, knowing one’s genetic status becomes essential for accessing these therapies when they become available.^[12]

Lifestyle Factors and Disease Progression

Emerging research suggests that lifestyle choices may influence disease progression even in people with genetic forms of frontotemporal dementia. Studies from specialized dementia centers have found that a physically and mentally active lifestyle appears to confer some resilience to the disease. People who maintain higher levels of physical activity and cognitive engagement may experience slower progression and better outcomes, even when they carry genetic mutations that make frontotemporal dementia virtually inevitable.^[17]

This research aligns with long-standing evidence about the protective effects of exercise and mental stimulation in Alzheimer’s disease and other forms of dementia. While lifestyle modifications cannot cure or prevent frontotemporal dementia in those genetically predestined to develop it, they may help people maintain function and quality of life for longer periods. Physical exercise, social engagement, and mentally stimulating activities appear to build a reserve that allows the brain to better cope with the damage caused by the disease.^[17]

Most common treatment methods

• Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Used to manage behavioral symptoms including apathy, depression, anxiety, agitation, and compulsive behaviors
  • Considered relatively safe in the dementia population
  • Often the first medication tried for behavioral symptoms in frontotemporal dementia
• Antipsychotic Medications
  • Rarely used due to safety concerns in dementia patients
  • May be considered only for severe challenging behavior when SSRIs have failed and behavior poses risk
  • Carry increased risk of stroke and death in people with dementia
• Speech and Language Therapy
  • Helps manage communication difficulties and language problems
  • Provides strategies for compensating for word-finding difficulties
  • Addresses swallowing problems to prevent aspiration pneumonia
  • Teaches families better ways to communicate with their loved one
• Occupational Therapy
  • Identifies problem areas in everyday activities like dressing and grooming
  • Develops practical solutions and adaptive strategies
  • Recommends home modifications to maintain independence and safety
• Physical Therapy
  • Addresses movement difficulties, balance problems, and muscle weakness
  • Designs exercise programs to maintain mobility and prevent falls
  • Helps preserve physical function as long as possible
• Behavioral Management Strategies
  • Non-pharmacological approaches tried before medications
  • Includes structured daily routines and distraction techniques
  • Involves creating calm, predictable environments
  • Focuses on accepting rather than challenging problematic behaviors
• Social Engagement Activities
  • Memory cafes and support groups provide social interaction
  • Adapted leisure activities maintain quality of life
  • Music therapy and other relaxation techniques